AURNEVO Trademark

Trademark Overview


On Wednesday, January 26, 2022, a trademark application was filed for AURNEVO with the United States Patent and Trademark Office. The USPTO has given the AURNEVO trademark a serial number of 97238718. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, November 19, 2024. This trademark is owned by Eli Lilly and Company. The AURNEVO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

General Information


Serial Number97238718
Word MarkAURNEVO
Filing DateWednesday, January 26, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, November 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 25, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 31, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Saturday, January 29, 2022NEW APPLICATION ENTERED
Monday, January 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 20, 2022ASSIGNED TO EXAMINER
Tuesday, September 20, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 5, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 25, 2022PUBLISHED FOR OPPOSITION
Tuesday, October 25, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 20, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 15, 2023SOU EXTENSION 1 FILED
Monday, May 15, 2023SOU EXTENSION 1 GRANTED
Wednesday, May 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 13, 2023SOU EXTENSION 2 FILED
Monday, November 13, 2023SOU EXTENSION 2 GRANTED
Wednesday, November 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 16, 2024SOU EXTENSION 3 FILED
Thursday, May 16, 2024SOU EXTENSION 3 GRANTED
Thursday, May 16, 2024SOU TEAS EXTENSION RECEIVED
Friday, May 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 19, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 19, 2024SOU EXTENSION 4 GRANTED
Tuesday, November 19, 2024SOU EXTENSION 4 FILED
Monday, May 15, 2023SOU TEAS EXTENSION RECEIVED